104 related articles for article (PubMed ID: 7757968)
61. Modulation of the beta-adrenergic-response in cultured rat heart cells. II. Mammary-derived growth inhibitor (MDGI) blocks induction of beta-adrenergic supersensitivity. Dissociation from lipid-binding activity of MDGI.
Wallukat G; Boehmer FD; Engstroem U; Langen P; Hollenberg M; Behlke J; Kuehn H; Grosse R
Mol Cell Biochem; 1991 Mar; 102(1):49-60. PubMed ID: 1646956
[TBL] [Abstract][Full Text] [Related]
62. Deletion of the gene encoding H-FABP/MDGI has no overt effects in the mammary gland.
Clark AJ; Neil C; Gusterson B; McWhir J; Binas B
Transgenic Res; 2000 Dec; 9(6):439-44. PubMed ID: 11206972
[TBL] [Abstract][Full Text] [Related]
63. Is the mammary-derived growth inhibitor (MDGI) related 70 kD antigen, identified in nuclei, a nuclear receptor for MDGI or its hydrophobic ligands?
Vogel F; Mueller T; Grosse R
Prog Histochem Cytochem; 1992; 26(1-4):159-63. PubMed ID: 1484958
[No Abstract] [Full Text] [Related]
64. Differentiation-promoting effects of mammary-derived growth inhibitor (MDGI) on pluripotent mouse embryonic stem cells.
Wobus AM; Zschiesche W; Grosse R
Virchows Arch B Cell Pathol Incl Mol Pathol; 1990; 59(6):339-42. PubMed ID: 1981402
[TBL] [Abstract][Full Text] [Related]
65. TMSB4Y is a candidate tumor suppressor on the Y chromosome and is deleted in male breast cancer.
Wong HY; Wang GM; Croessmann S; Zabransky DJ; Chu D; Garay JP; Cidado J; Cochran RL; Beaver JA; Aggarwal A; Liu ML; Argani P; Meeker A; Hurley PJ; Lauring J; Park BH
Oncotarget; 2015 Dec; 6(42):44927-40. PubMed ID: 26702755
[TBL] [Abstract][Full Text] [Related]
66. Antibodies against mammary derived growth inhibitor (MDGI) react with a fibroblast growth inhibitor and with heart fatty acid binding protein.
Böhmer FD; Sun Q; Pepperle M; Müller T; Eriksson U; Wang JL; Grosse R
Biochem Biophys Res Commun; 1987 Nov; 148(3):1425-31. PubMed ID: 3318832
[TBL] [Abstract][Full Text] [Related]
67. Hydrodynamic and circular dichroic analysis of mammary-derived growth inhibitor (MDGI).
Behlke J; Mieth M; Böhmer FD; Grosse R
Biochem Biophys Res Commun; 1989 May; 161(1):363-70. PubMed ID: 2730664
[TBL] [Abstract][Full Text] [Related]
68. Isolation of genes overexpressed in freshly isolated breast cancer specimens.
Kurt RA; Urba WJ; Schoof DD
Breast Cancer Res Treat; 2000 Jan; 59(1):41-8. PubMed ID: 10752678
[TBL] [Abstract][Full Text] [Related]
69. Correspondence re: Y.E. Shi et al., Antitumor activity of the novel human breast cancer growth inhibitor, mammary-derived growth inhibitor-related gene, MRG. Cancer Res., 57: 3084-3091, 1997.
Hohoff C; Spener F
Cancer Res; 1998 Sep; 58(17):4015-7. PubMed ID: 9731516
[No Abstract] [Full Text] [Related]
70. Tissue factor expression in normal and abnormal mammary gland.
Luther T; Flössel C; Albrecht S; Kotzsch M; Müller M
Nat Med; 1996 May; 2(5):491-2. PubMed ID: 8616693
[No Abstract] [Full Text] [Related]
71. SELENOF is a new tumor suppressor in breast cancer.
Zigrossi A; Hong LK; Ekyalongo RC; Cruz-Alvarez C; Gornick E; Diamond AM; Kastrati I
Oncogene; 2022 Feb; 41(9):1263-1268. PubMed ID: 35082382
[TBL] [Abstract][Full Text] [Related]
72. A histochemical evaluation of the structure of mammary duct walls.
TEDESCHI LG; BYRNE JJ
Surg Gynecol Obstet; 1962 May; 114():559-62. PubMed ID: 13920068
[No Abstract] [Full Text] [Related]
73. Correction: Complement inhibitor CSMD1 acts as tumor suppressor in human breast cancer.
Escudero-Esparza A; Bartoschek M; Gialeli C; Okroj M; Owen S; Jirström K; Orimo A; Jiang WG; Pietras K; Blom AM
Oncotarget; 2023 May; 14():481-482. PubMed ID: 37204255
[No Abstract] [Full Text] [Related]
74. Structural Insights into Mouse H-FABP.
Wang L; Zhang H; Lv P; Li Y; Teng M; Liu Y; Wu D
Life (Basel); 2022 Sep; 12(9):. PubMed ID: 36143481
[TBL] [Abstract][Full Text] [Related]
75. Association of FABP5 expression with poor survival in triple-negative breast cancer: implication for retinoic acid therapy.
Liu RZ; Graham K; Glubrecht DD; Germain DR; Mackey JR; Godbout R
Am J Pathol; 2011 Mar; 178(3):997-1008. PubMed ID: 21356353
[TBL] [Abstract][Full Text] [Related]
76. Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab.
Brand TM; Iida M; Wheeler DL
Cancer Biol Ther; 2011 May; 11(9):777-92. PubMed ID: 21293176
[TBL] [Abstract][Full Text] [Related]
77. Gene expression profiles in Atlantic salmon adipose-derived stromo-vascular fraction during differentiation into adipocytes.
Todorcević M; Skugor S; Krasnov A; Ruyter B
BMC Genomics; 2010 Jan; 11():39. PubMed ID: 20078893
[TBL] [Abstract][Full Text] [Related]
78. The influence of feeding linoleic, gamma-linolenic and docosahexaenoic acid rich oils on rat brain tumor fatty acids composition and fatty acid binding protein 7 mRNA expression.
Nasrollahzadeh J; Siassi F; Doosti M; Eshraghian MR; Shokri F; Modarressi MH; Mohammadi-Asl J; Abdi K; Nikmanesh A; Karimian SM
Lipids Health Dis; 2008 Nov; 7():45. PubMed ID: 19014610
[TBL] [Abstract][Full Text] [Related]
79. Combined analysis of murine and human microarrays and ChIP analysis reveals genes associated with the ability of MYC to maintain tumorigenesis.
Wu CH; Sahoo D; Arvanitis C; Bradon N; Dill DL; Felsher DW
PLoS Genet; 2008 Jun; 4(6):e1000090. PubMed ID: 18535662
[TBL] [Abstract][Full Text] [Related]
80. Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets.
Furuhashi M; Hotamisligil GS
Nat Rev Drug Discov; 2008 Jun; 7(6):489-503. PubMed ID: 18511927
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
